

# Stephan Menne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/896487/publications.pdf>

Version: 2024-02-01

62  
papers

1,980  
citations

201658  
27  
h-index

254170  
43  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1506  
citing authors

#	ARTICLE	IF	CITATIONS
1	4-Oxo-octahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 58, 128518.	2.2	3
2	Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
3	Host cell-dependent late entry step as determinant of hepatitis B virus infection. <i>PLoS Pathogens</i> , 2022, 18, e1010633.	4.7	8
4	Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B. <i>Hepatology</i> , 2021, 73, 53-67.	7.3	56
5	Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus. <i>Medicinal Chemistry Research</i> , 2021, 30, 459-472.	2.4	6
6	Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B. <i>Viruses</i> , 2021, 13, 648.	3.3	8
7	Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 509-535.	2.0	11
8	Involvement of Innate Immune Receptors in the Resolution of Acute Hepatitis B in Woodchucks. <i>Frontiers in Immunology</i> , 2021, 12, 713420.	4.8	2
9	Characterization and Application of Precore/Core-Related Antigens in Animal Models of Hepatitis B Virus Infection. <i>Hepatology</i> , 2021, 74, 99-115.	7.3	19
10	Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks. <i>Cells</i> , 2021, 10, 2321.	4.1	6
11	Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects. <i>Frontiers in Immunology</i> , 2021, 12, 745802.	4.8	3
12	Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. <i>Current HIV Research</i> , 2020, 18, 19-28.	0.5	9
13	Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon- $\alpha$ in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus. <i>Hepatology Communications</i> , 2020, 4, 916-931.	4.3	16
14	Suitability of the woodchuck HCC as a preclinical model for evaluation of intra-arterial therapies. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 98-102.	3.3	7
15	Liver-Targeted Toll-Like Receptor 7 Agonist Combined With Entecavir Promotes a Functional Cure in the Woodchuck Model of Hepatitis B Virus. <i>Hepatology Communications</i> , 2019, 3, 1296-1310.	4.3	27
16	Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. <i>Cancers</i> , 2019, 11, 681.	3.7	33
17	Down-regulation of hepatitis delta virus super-infection in the woodchuck model. <i>Virology</i> , 2019, 531, 100-113.	2.4	3
18	The Genome Sequence of the Eastern Woodchuck ( <i>Marmota monax</i> ) – A Preclinical Animal Model for Chronic Hepatitis B. <i>G3: Genes, Genomes, Genetics</i> , 2019, 9, 3943-3952.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Innate and adaptive immunity associated with resolution of acute woodchuck hepatitis virus infection in adult woodchucks. PLoS Pathogens, 2019, 15, e1008248.	4.7	17
20	Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Current Opinion in Virology, 2018, 30, 9-17.	5.4	36
21	Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLoS ONE, 2018, 13, e0190058.	2.5	37
22	Prevention of liver tumor formation in woodchucks with established hepatocellular carcinoma by treatment with cationic liposome-DNA complexes. BMC Cancer, 2017, 17, 172.	2.6	13
23	Measurement of Antiviral Effect and Innate Immune Response During Treatment of Primary Woodchuck Hepatocytes. Methods in Molecular Biology, 2017, 1540, 277-294.	0.9	2
24	Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS ONE, 2017, 12, e0169631.	2.5	38
25	Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS ONE, 2016, 11, e0161313.	2.5	56
26	Superinfection with Woodchuck Hepatitis Virus Strain WHVNY of Livers Chronically Infected with Strain WHV7. Journal of Virology, 2015, 89, 384-405.	3.4	13
27	Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks. Virus Research, 2015, 205, 12-21.	2.2	4
28	Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. Journal of Hepatology, 2015, 62, 1237-1245.	3.7	191
29	Infection Patterns Induced in Naive Adult Woodchucks by Virions of Woodchuck Hepatitis Virus Collected during either the Acute or Chronic Phase of Infection. Journal of Virology, 2015, 89, 8749-8763.	3.4	7
30	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. Journal of Hepatology, 2015, 63, 329-336.	3.7	21
31	AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. PLoS ONE, 2015, 10, e0144383.	2.5	18
32	Intrahepatic Transcriptional Signature Associated with Response to Interferon- $\alpha$ Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS Pathogens, 2015, 11, e1005103.	4.7	42
33	Envelope Proteins Derived from Naturally Integrated Hepatitis B Virus DNA Support Assembly and Release of Infectious Hepatitis Delta Virus Particles. Journal of Virology, 2014, 88, 5742-5754.	3.4	71
34	Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. Hepatology, 2013, 57, 13-22.	7.3	43
35	Expression of matrix metalloproteinases and their inhibitors in the woodchuck model of hepatocellular carcinoma. Journal of Medical Virology, 2013, 85, 1127-1138.	5.0	11
36	Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. Hepatology, 2012, 56, 1240-1251.	7.3	42

#	ARTICLE	IF	CITATIONS
37	Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. <i>Hepatology</i> , 2012, 56, 76-85.	7.3	28
38	Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 474-483.	7.3	23
39	Transcriptomic analysis of the woodchuck model of chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 820-830.	7.3	88
40	Electroporation Enhances Immunogenicity of a DNA Vaccine Expressing Woodchuck Hepatitis Virus Surface Antigen in Woodchucks. <i>Journal of Virology</i> , 2011, 85, 4853-4862.	3.4	17
41	Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12. <i>Journal of Virology</i> , 2009, 83, 2663-2674.	3.4	34
42	Semliki Forest Virus Expressing Interleukin-12 Induces Antiviral and Antitumoral Responses in Woodchucks with Chronic Viral Hepatitis and Hepatocellular Carcinoma. <i>Journal of Virology</i> , 2009, 83, 12266-12278.	3.4	42
43	Correlation of Virus and Host Response Markers with Circulating Immune Complexes during Acute and Chronic Woodchuck Hepatitis Virus Infection. <i>Journal of Virology</i> , 2009, 83, 1579-1591.	3.4	13
44	Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposomeâ€DNA complexes as adjuvant. <i>Journal of Medical Virology</i> , 2009, 81, 1760-1772.	5.0	11
45	Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3617-3632.	3.2	33
46	Antiviral Effect of Orally Administered (âˆ™)-Î²-2-Aminopurine Dioxolane in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3177-3184.	3.2	9
47	Chemoimmunotherapy of Chronic Hepatitis B Virus Infection in the Woodchuck Model Overcomes Immunologic Tolerance and Restores T-Cell Responses to Pre-S and S Regions of the Viral Envelope Protein. <i>Journal of Virology</i> , 2007, 81, 10614-10624.	3.4	27
48	Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection. <i>Hepatology</i> , 2007, 45, 614-622.	7.3	24
49	The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2007, 13, 104.	3.3	150
50	Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2720-2728.	3.2	32
51	Measurement of Cell-Mediated Immune Response in Woodchucks. , 2004, 96, 27-36.		4
52	Kinetics of viremia and acute liver injury in relation to outcome of neonatal woodchuck hepatitis virus infection. <i>Journal of Medical Virology</i> , 2004, 72, 406-415.	5.0	17
53	Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. <i>Gastroenterology</i> , 2004, 127, S283-S293.	1.3	130
54	Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. <i>Antiviral Therapy</i> , 2004, 9, 937-52.	1.0	15

#	ARTICLE	IF	CITATIONS
55	Clevudine Therapy with Vaccine Inhibits Progression of Chronic Hepatitis and Delays Onset of Hepatocellular Carcinoma in Chronic Woodchuck Hepatitis Virus Infection. <i>Antiviral Therapy</i> , 2004, 9, 937-952.	1.0	44
56	Role of type 1 versus type 2 immune responses in liver during the onset of chronic woodchuck hepatitis virus infection. <i>Hepatology</i> , 2003, 37, 771-780.	7.3	34
57	Immunization with Surface Antigen Vaccine Alone and after Treatment with 1-(2-Fluoro-5-Methyl-1 <sup>2</sup> -l-Arabinofuranosyl)-Uracil (l-FMAU) Breaks Humoral and Cell-Mediated Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection. <i>Journal of Virology</i> , 2002, 76, 5305-5314.	3.4	81
58	Deficiencies in the Acute-Phase Cell-Mediated Immune Response to Viral Antigens Are Associated with Development of Chronic Woodchuck Hepatitis Virus Infection following Neonatal Inoculation. <i>Journal of Virology</i> , 2002, 76, 1769-1780.	3.4	82
59	Immunogenic Effects of Woodchuck Hepatitis Virus Surface Antigen Vaccine in Combination with Antiviral Therapy: Breaking of Humoral and Cellular Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection. <i>Intervirology</i> , 2002, 45, 237-250.	2.8	43
60	Real-time polymerase chain reaction assays for leukocyte CD and cytokine mRNAs of the Eastern woodchuck ( <i>Marmota monax</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2002, 87, 97-105.	1.2	15
61	Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). <i>Nature Medicine</i> , 1999, 5, 1125-1126.	30.7	29
62	T-Cell Response to Woodchuck Hepatitis Virus (WHV) Antigens during Acute Self-Limited WHV Infection and Convalescence and after Viral Challenge. <i>Journal of Virology</i> , 1998, 72, 6083-6091.	3.4	61